TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04669795

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cissus Quadrangularis
Description: Drug with osteogenic potential given to the patients after consolidation period. dose was two capsules once /day with meals for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cissus Quadrangularis
Description: Drug with osteogenic potential given to the patients after consolidation period. dose was two capsules once /day with meals for 6 weeks
Study: NCT00822094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Salvage Therapy
Study: NCT02644551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CELEXT07

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penlac

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vehicle solution
Study: NCT01534559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medicines Management Outpatient service
Description: New customised clinical pharmacy service (medicines management clinic and follow-up phone calls)
Study: NCT02724839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group nutrition sessions
Description: The intervention will consist of 6 nutrition group sessions co-led by parent and a professional from the community who will rotate at each session. Group nutrition sessions will consist of a facilitated discussion of benefits and barriers to healthy eating, a short lesson led by the content expert, and a fun game or activity to reinforce the lesson. Three non-concurrent phases of the study will compare the efficacy of the group sessions when offered biweekly (Arm 1), monthly (Arm 2) and weekly (Arm 3).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group nutrition sessions
Description: The intervention will consist of 6 nutrition group sessions co-led by parent and a professional from the community who will rotate at each session. Group nutrition sessions will consist of a facilitated discussion of benefits and barriers to healthy eating, a short lesson led by the content expert, and a fun game or activity to reinforce the lesson. Three non-concurrent phases of the study will compare the efficacy of the group sessions when offered biweekly (Arm 1), monthly (Arm 2) and weekly (Arm 3).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group nutrition sessions
Description: The intervention will consist of 6 nutrition group sessions co-led by parent and a professional from the community who will rotate at each session. Group nutrition sessions will consist of a facilitated discussion of benefits and barriers to healthy eating, a short lesson led by the content expert, and a fun game or activity to reinforce the lesson. Three non-concurrent phases of the study will compare the efficacy of the group sessions when offered biweekly (Arm 1), monthly (Arm 2) and weekly (Arm 3).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Parent and child dyads will each receive a Fitbit Flex wearable device at the second session. This device will be used by participants and investigators to motivate and track participants' physical activity for up to 9 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Parent and child dyads will each receive a Fitbit Flex wearable device at the second session. This device will be used by participants and investigators to motivate and track participants' physical activity for up to 9 months.
Study: NCT02681783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aflibercept
Description: Therapeutic/Pharmacological Classification: VEGF - Anti-neovascularization agent Route(s) of Administration: Intravitreal Injection Dosage Form: Solution 40 mg/ml Proposed Indication: Treatment of Pigment Epithelial Detachments (PEDs) associated with neovascular Age-related Macular Degeneration (nAMD), Central serous chorioretinopathy (CSR), and idiopathic Poplypoidal Choroidal Vasculopathy (iPCV).
Study: NCT02724839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Parent and child dyads will each receive a Fitbit Flex wearable device at the second session. This device will be used by participants and investigators to motivate and track participants' physical activity for up to 9 months.
Study: NCT03245684

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: assessment of inflammatory response during PSV
Description: assessment cytokines level in BAL and plasma

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: assessment of inflammatory response during PSV
Description: assessment cytokines level in BAL and plasma
Study: NCT03320057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Patients will receive Mifeprex® (mifepristone) by pharmacy rather than standard care at clinic visit

Intervention type: OTHER
Group type: OTHER
Intervention: Training on mifepristone dispensing
Description: Pharmacists were offered a training on medication abortion and mifepristone dispensing
Study: NCT02655640

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires will be provided to patients

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires will be provided to patients
Study: NCT01705990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SeV-G(NP) (0.2mL, 2x10^7 CIU)
Description: Delivered intranasally by drops

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SeV-G(NP) (0.2mL, 2x10^8 CIU)
Description: Delivered intranasally by drops
Study: NCT01705392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg q3w
Study: NCT00981383

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid Supplement
Description: 3 capsules (3x1g) fish oil-derived concentrated ethyl esters, providing 1.9 g omega-3 fatty acids (1.2 g EPA and 0.6 g DHA, with 0.1 g other omega-3 fatty acids)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules (3x1g) of 50/50 soybean/corn oil blend containing less than 0.12 g of omega-3 fatty acids with negligible EPA and DHA
Study: NCT01815333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feraheme
Description: 6 mg of iron/kg (maximum 510 mg/dose) injected at a rate of 1 ml/sec (30 mg/sec) or slower after initial MRI.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI scan performed before Feraheme injection. After Feraheme injection, MRI scan performed 2 days later, and then again the following day.
Study: NCT02446223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inggenol Mebutate 0.015%
Study: NCT02411942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene Gel 0.3%
Description: Adapalene Gel 0.3% applied to the entire face once daily for 84 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Differin®
Description: Differin® applied to the entire face once daily for 84 consecutive days
Study: NCT01705392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol 80 mg x 1
Study: NCT02638519

Intervention type: DEVICE
Group type: OTHER
Intervention: 1H-129Xe Dual-Tuned Quadrature Head Coil
Description: A 1H-129Xe dual-tuned quadrature head coil (Clinical MR Solutions, LLC) will be used in this study. The RF coil will be used to acquire MRI images of the human brain after inhalation of hyperpolarized xenon-129 gas, and permits the acquisition of both conventional proton and HP xenon gas images.
Study: NCT03302572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief information group
Description: Patients will be given oral brief information about the existence of advance directives after resolving the reason for the visit for which they had come. This information will not last more than 3 minutes and will not be repeated on successive visits within the recruitment period. Also, an informative triptych will be given to the patient so that he can read it at home. These leaflets have been made by the regional Department of Health. They will be advised that we can extend the information or help them to do the document in the near future if they want, we will inform that we would wait for the answer 3 months. In case of interest, they can leave their information in the User Service by specifying name, telephone number and reference doctor or ask for an appointment again.
Study: NCT01705990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SeV-G(NP) (0.2mL, 2x10^8 CIU)
Description: Delivered intranasally by drops

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SeV-G(NP) (0.2mL, 2x10^8 CIU)
Description: Delivered intranasally by drops

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN (0.5mL)
Description: (1x10\^10 vp) Delivered intramuscularly by standard syringe and needle injection
Study: NCT03844997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palcociclib
Description: Palbociclib is an investigational (experimental) drug that works to induce early G1 arrest by inhibiting CDK4/6, which are two types of CDKs that are overexpressed in AML cell cancer lines. Palbociclib is experimental because it is not approved by the Food and Drug Administration (FDA).~Palbociclib will be supplied as capsules or tablets containing 125 mg equivalents of Palbociclib free base

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 (daunorubicin and cytarabine) liposome for injection is a combination of daunorubicin and cytarabine in a 1:5 molar ratio encapsulated in liposomes for intravenous administration. CPX-351 is an investigational (experimental) drug that works as formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. CPX-351 is experimental because it is not approved by the Food and Drug Administration (FDA).
Study: NCT01705990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN (0.5mL)
Description: (1x10\^10 vp) Delivered intramuscularly by standard syringe and needle injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN (0.5mL)
Description: (1x10\^10 vp) Delivered intramuscularly by standard syringe and needle injection
Study: NCT02007993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDT
Description: A single session of PDT will be performed with the Chimiolux® photosensitizer at a concentration of 0.005% applied over the middle and posterior thirds of the dorsum of the tongue.~Nine points will be irradiated, the device will be previously calibrated with a wavelength of 660 nm, power of 100 mW, energy of 9 joules for 90 seconds per point in Groups 2 and 4 and 12 joules for 120 second per point in Groups 3 and 5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDT
Description: A single session of PDT will be performed with the Chimiolux® photosensitizer at a concentration of 0.005% applied over the middle and posterior thirds of the dorsum of the tongue.~Nine points will be irradiated, the device will be previously calibrated with a wavelength of 660 nm, power of 100 mW, energy of 9 joules for 90 seconds per point in Groups 2 and 4 and 12 joules for 120 second per point in Groups 3 and 5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDT
Description: A single session of PDT will be performed with the Chimiolux® photosensitizer at a concentration of 0.005% applied over the middle and posterior thirds of the dorsum of the tongue.~Nine points will be irradiated, the device will be previously calibrated with a wavelength of 660 nm, power of 100 mW, energy of 9 joules for 90 seconds per point in Groups 2 and 4 and 12 joules for 120 second per point in Groups 3 and 5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDT
Description: A single session of PDT will be performed with the Chimiolux® photosensitizer at a concentration of 0.005% applied over the middle and posterior thirds of the dorsum of the tongue.~Nine points will be irradiated, the device will be previously calibrated with a wavelength of 660 nm, power of 100 mW, energy of 9 joules for 90 seconds per point in Groups 2 and 4 and 12 joules for 120 second per point in Groups 3 and 5

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tongue Scraper
Description: The pacient will scrap the tongue 10 times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tongue Scraper
Description: The pacient will scrap the tongue 10 times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tongue Scraper
Description: The pacient will scrap the tongue 10 times.
Study: NCT03460938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: RIPC: 3 periods of 5 minutes of ischemia followed by 5 minutes of reperfusion are created by inflating a blood pressure cuff on the upper extremity after induction of anesthesia and prior to surgery.
Study: NCT01846104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50-μg booster dose RVEc
Description: Subjects will be recruited from the 10 subjects who received three 50-μg doses of RVEc during the Phase 1 trial. Subjects will receive a single booster dose only and will be followed for 6 months after vaccination.
Study: NCT01970657

Intervention type: BIOLOGICAL
Intervention: No treatment specified
Description: No intervention

Intervention type: BIOLOGICAL
Intervention: No treatment
Description: None specified
Study: NCT04961307

Intervention type: DRUG
Intervention: Trastuzumab
Description: 30 female breast cancer patients using trastuzumab, collected demographic and clinical information of all patients before chemotherapy, performed echocardiography (conventional echocardiography, three-dimensional spot tracking technology), and collected blood samples to detect plasma biology Markers (TnT, BNP, GDF-15, topoisomerase
Study: NCT01952925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Artery denervation
Description: RA denervation performed as part of afib ablation procedure
Study: NCT00851630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination zidovudine/lamivudine/abacavir
Description: All subjects will receive fixed dose combination zidovudine(300 mg) / lamivudine (150 mg) / abacavir (300 mg) by mouth twice daily. Medications will be provided as long as deemed beneficial by the site investigator and study subject for up to two years. Toxicity substitutions are allowed per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination zidovudine/lamivudine/abacavir
Description: All subjects will receive fixed dose combination zidovudine(300 mg) / lamivudine (150 mg) / abacavir (300 mg) by mouth twice daily. Medications will be provided as long as deemed beneficial by the site investigator and study subject for up to two years. Toxicity substitutions are allowed per protocol.
Study: NCT02856178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: F901318 treatment starting after completion of chemotherapy. Max. 14 days of intravenous F901318 b.i.d. treatment, followed by one oral dose of F901318. Loading doses 4 mg/kg b.i.d. , maintenance doses 2 mg/kg b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin
Description: Intravenous Caspofungin treatment starting during chemotherapy for concomitant prophylaxis of fungal infection. Loading dose 70 mg q.d., maintenance doses 50 mg q.d.
Study: NCT02772107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is a nonclassic oral alkylating agent. Temozolomide will be given alone as maintenance therapy in patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.
Study: NCT02411942

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (vehicle of the test product) applied to the entire face once daily for 84 consecutive days
Study: NCT02772107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: first-line chemotherapy
Description: first-line chemotherapy must be platinum-based: cisplatin(75mg/m2 for d1) or carboplatin（AUC 5 for d1) combined with etoposide（100mg/m2 for d1-d3）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: first-line chemotherapy
Description: first-line chemotherapy must be platinum-based: cisplatin(75mg/m2 for d1) or carboplatin（AUC 5 for d1) combined with etoposide（100mg/m2 for d1-d3）

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Description: Prophylactic cranial irradiation was allowed if necessary

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Description: Prophylactic cranial irradiation was allowed if necessary

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiotherapy
Description: thoracic radiotherapy was allowed if necessary

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiotherapy
Description: thoracic radiotherapy was allowed if necessary
Study: NCT04450446

Intervention type: DRUG
Intervention: Low molecular weight heparin
Description: Anticoagulation therapy

Intervention type: DRUG
Intervention: Low molecular weight heparin
Description: Anticoagulation therapy

Intervention type: DRUG
Intervention: Low molecular weight heparin
Description: Anticoagulation therapy
Study: NCT02903355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-methionine
Description: D-methionine, oral liquid suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
Study: NCT00931879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3-ethyl esters
Description: Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (\>500 mg/dL) triglyceride (TG) levels in adult patients.
Study: NCT01803399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 1200 mg
Description: GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 1200 mg (3 vials) will be administered IV over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 3000 mg
Description: GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 3000 mg (8 vials) will be administered IV over 60 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as 0.9% sodium chloride solution. Single dose of placebo will be administered IV over 60 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin will be supplied as oblong, dull red film coated tablets of 400 mg strength. Single dose of moxifloxacin 400 mg will be administered orally
Study: NCT01705392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: Enalapril 5 mg x 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: dacarbazine 1000 mg/m2 q3w
Study: NCT03864328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-1601
Description: Inhaled RVT-1601 administered TID via eFlow nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-1601
Description: Inhaled RVT-1601 administered TID via eFlow nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-1601
Description: Inhaled RVT-1601 administered TID via eFlow nebulizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled Placebo administered TID via eFlow nebulizer
Study: NCT00931879

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
Study: NCT03322566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously every 3 weeks.
Study: NCT01863004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study: NCT02715063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval
Description: Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
Study: NCT04281303

Intervention type: PROCEDURE
Intervention: Endoscopic vertical gastroplasty
Description: endoscopic vertical gastroplasty + lifestyle modification
Study: NCT03714971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp embedded in smoking cessation service
Description: The routine service delivery was ongoing as the intervention was conducted. In addition to the routine procedures in service delivery described above, WhatsApp messages were sent according to the plan.
Study: NCT00282412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplantation
Description: Allogeneic Hematopoietic Stem Cell Transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: inhibits DNA synthesis or repair

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Causes prevention of cell division by forming adducts with DNA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath 1H
Description: humanized monoclonal antibody against CD52 antigen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCSF
Description: Hematopoietic growth factor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporins
Description: immune suppressive drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: immune suppressive drug
Study: NCT01536743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD0332991
Description: 30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle).